お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はゲノム創薬市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはゲノム創薬の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のゲノム創薬市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはゲノム創薬のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にゲノム創薬市場を分類しています。本研究に含まれる主な企業は：Abbott Laboratories、Affymetrix, Inc.、Assurex Health, Inc、Astrazeneca、GeneDX、Illumina, Inc.、Laboratory Corporation of America Holdings、Myriad Genetics, Inc.、Pathway Genomics、Pfizer, Inc、Qiagen, Inc.、Rocheg、Teva Pharmaceutical Industries Ltd.、Thermo Fisher Scientific、Transgenomic, Inc.

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Polymerase Chain Reaction (PCR)
    Microarray
    Sequencing
    Other

用途別の市場セグメント：
    Cardiovascular Diseases (CVD)
    Central Nervous System (CNS)
    Cancer/Oncology
    Infectious Diseases
    Other

本レポートの詳細内容
世界のゲノム創薬市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、ゲノム創薬タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のゲノム創薬収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のゲノム創薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、ゲノム創薬市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

ゲノム創薬のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：ゲノム創薬のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：ゲノム創薬の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章ゲノム創薬企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：ゲノム創薬の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：ゲノム創薬の主要企業の概要を提供し、製品の説明と仕様、ゲノム創薬の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Market Analysis and Insights: Global Pharmacogenomics (PGx) Market
The global Pharmacogenomics (PGx) market is projected to grow from US$ 8569.5 million in 2024 to US$ 14590 million by 2030, at a Compound Annual Growth Rate (CAGR) of 9.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Pharmacogenomics (PGx) market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Pharmacogenomics (PGx), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Pharmacogenomics (PGx), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pharmacogenomics (PGx) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Pharmacogenomics (PGx) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Pharmacogenomics (PGx) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Abbott Laboratories, Affymetrix, Inc., Assurex Health, Inc, Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc. and Pathway Genomics, etc.
Market Segmentation
By Company
    Abbott Laboratories
    Affymetrix, Inc.
    Assurex Health, Inc
    Astrazeneca
    GeneDX
    Illumina, Inc.
    Laboratory Corporation of America Holdings
    Myriad Genetics, Inc.
    Pathway Genomics
    Pfizer, Inc
    Qiagen, Inc.
    Rocheg
    Teva Pharmaceutical Industries Ltd.
    Thermo Fisher Scientific
    Transgenomic, Inc.

Segment by Type
    Polymerase Chain Reaction (PCR)
    Microarray
    Sequencing
    Other

Segment by Application
    Cardiovascular Diseases (CVD)
    Central Nervous System (CNS)
    Cancer/Oncology
    Infectious Diseases
    Other

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Pharmacogenomics (PGx) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacogenomics (PGx) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmacogenomics (PGx) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Pharmacogenomics (PGx) Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Polymerase Chain Reaction (PCR)
    Table 3. Key Players of Microarray
    Table 4. Key Players of Sequencing
    Table 5. Key Players of Other
    Table 6. Global Pharmacogenomics (PGx) Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 7. Global Pharmacogenomics (PGx) Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Pharmacogenomics (PGx) Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global Pharmacogenomics (PGx) Market Share by Region (2019-2024)
    Table 10. Global Pharmacogenomics (PGx) Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global Pharmacogenomics (PGx) Market Share by Region (2025-2030)
    Table 12. Pharmacogenomics (PGx) Market Trends
    Table 13. Pharmacogenomics (PGx) Market Drivers
    Table 14. Pharmacogenomics (PGx) Market Challenges
    Table 15. Pharmacogenomics (PGx) Market Restraints
    Table 16. Global Pharmacogenomics (PGx) Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global Pharmacogenomics (PGx) Revenue Share by Players (2019-2024)
    Table 18. Global Top Pharmacogenomics (PGx) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics (PGx) as of 2023)
    Table 19. Global Pharmacogenomics (PGx) Industry Ranking 2022 VS 2023 VS 2024
    Table 20. Global 5 Largest Players Market Share by Pharmacogenomics (PGx) Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Global Key Players of Pharmacogenomics (PGx), Headquarters and Area Served
    Table 22. Global Key Players of Pharmacogenomics (PGx), Product and Application
    Table 23. Global Key Players of Pharmacogenomics (PGx), Product and Application
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Pharmacogenomics (PGx) Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global Pharmacogenomics (PGx) Revenue Market Share by Type (2019-2024)
    Table 27. Global Pharmacogenomics (PGx) Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global Pharmacogenomics (PGx) Revenue Market Share by Type (2025-2030)
    Table 29. Global Pharmacogenomics (PGx) Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global Pharmacogenomics (PGx) Revenue Share by Application (2019-2024)
    Table 31. Global Pharmacogenomics (PGx) Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global Pharmacogenomics (PGx) Revenue Share by Application (2025-2030)
    Table 33. North America Pharmacogenomics (PGx) Market Size by Type (2019-2024) & (US$ Million)
    Table 34. North America Pharmacogenomics (PGx) Market Size by Type (2025-2030) & (US$ Million)
    Table 35. North America Pharmacogenomics (PGx) Market Size by Application (2019-2024) & (US$ Million)
    Table 36. North America Pharmacogenomics (PGx) Market Size by Application (2025-2030) & (US$ Million)
    Table 37. North America Pharmacogenomics (PGx) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. North America Pharmacogenomics (PGx) Market Size by Country (2019-2024) & (US$ Million)
    Table 39. North America Pharmacogenomics (PGx) Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Europe Pharmacogenomics (PGx) Market Size by Type (2019-2024) & (US$ Million)
    Table 41. Europe Pharmacogenomics (PGx) Market Size by Type (2025-2030) & (US$ Million)
    Table 42. Europe Pharmacogenomics (PGx) Market Size by Application (2019-2024) & (US$ Million)
    Table 43. Europe Pharmacogenomics (PGx) Market Size by Application (2025-2030) & (US$ Million)
    Table 44. Europe Pharmacogenomics (PGx) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Europe Pharmacogenomics (PGx) Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Europe Pharmacogenomics (PGx) Market Size by Country (2025-2030) & (US$ Million)
    Table 47. China Pharmacogenomics (PGx) Market Size by Type (2019-2024) & (US$ Million)
    Table 48. China Pharmacogenomics (PGx) Market Size by Type (2025-2030) & (US$ Million)
    Table 49. China Pharmacogenomics (PGx) Market Size by Application (2019-2024) & (US$ Million)
    Table 50. China Pharmacogenomics (PGx) Market Size by Application (2025-2030) & (US$ Million)
    Table 51. Asia Pharmacogenomics (PGx) Market Size by Type (2019-2024) & (US$ Million)
    Table 52. Asia Pharmacogenomics (PGx) Market Size by Type (2025-2030) & (US$ Million)
    Table 53. Asia Pharmacogenomics (PGx) Market Size by Application (2019-2024) & (US$ Million)
    Table 54. Asia Pharmacogenomics (PGx) Market Size by Application (2025-2030) & (US$ Million)
    Table 55. Asia Pharmacogenomics (PGx) Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 56. Asia Pharmacogenomics (PGx) Market Size by Region (2019-2024) & (US$ Million)
    Table 57. Asia Pharmacogenomics (PGx) Market Size by Region (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Size by Type (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Size by Type (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Size by Application (2019-2024) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Size by Application (2025-2030) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 63. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Size by Country (2019-2024) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Size by Country (2025-2030) & (US$ Million)
    Table 65. Abbott Laboratories Company Details
    Table 66. Abbott Laboratories Business Overview
    Table 67. Abbott Laboratories Pharmacogenomics (PGx) Product
    Table 68. Abbott Laboratories Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 69. Abbott Laboratories Recent Developments
    Table 70. Affymetrix, Inc. Company Details
    Table 71. Affymetrix, Inc. Business Overview
    Table 72. Affymetrix, Inc. Pharmacogenomics (PGx) Product
    Table 73. Affymetrix, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 74. Affymetrix, Inc. Recent Developments
    Table 75. Assurex Health, Inc Company Details
    Table 76. Assurex Health, Inc Business Overview
    Table 77. Assurex Health, Inc Pharmacogenomics (PGx) Product
    Table 78. Assurex Health, Inc Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 79. Assurex Health, Inc Recent Developments
    Table 80. Astrazeneca Company Details
    Table 81. Astrazeneca Business Overview
    Table 82. Astrazeneca Pharmacogenomics (PGx) Product
    Table 83. Astrazeneca Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 84. Astrazeneca Recent Developments
    Table 85. GeneDX Company Details
    Table 86. GeneDX Business Overview
    Table 87. GeneDX Pharmacogenomics (PGx) Product
    Table 88. GeneDX Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 89. GeneDX Recent Developments
    Table 90. Illumina, Inc. Company Details
    Table 91. Illumina, Inc. Business Overview
    Table 92. Illumina, Inc. Pharmacogenomics (PGx) Product
    Table 93. Illumina, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 94. Illumina, Inc. Recent Developments
    Table 95. Laboratory Corporation of America Holdings Company Details
    Table 96. Laboratory Corporation of America Holdings Business Overview
    Table 97. Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product
    Table 98. Laboratory Corporation of America Holdings Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 99. Laboratory Corporation of America Holdings Recent Developments
    Table 100. Myriad Genetics, Inc. Company Details
    Table 101. Myriad Genetics, Inc. Business Overview
    Table 102. Myriad Genetics, Inc. Pharmacogenomics (PGx) Product
    Table 103. Myriad Genetics, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 104. Myriad Genetics, Inc. Recent Developments
    Table 105. Pathway Genomics Company Details
    Table 106. Pathway Genomics Business Overview
    Table 107. Pathway Genomics Pharmacogenomics (PGx) Product
    Table 108. Pathway Genomics Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 109. Pathway Genomics Recent Developments
    Table 110. Pfizer, Inc Company Details
    Table 111. Pfizer, Inc Business Overview
    Table 112. Pfizer, Inc Pharmacogenomics (PGx) Product
    Table 113. Pfizer, Inc Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 114. Pfizer, Inc Recent Developments
    Table 115. Qiagen, Inc. Company Details
    Table 116. Qiagen, Inc. Business Overview
    Table 117. Qiagen, Inc. Pharmacogenomics (PGx) Product
    Table 118. Qiagen, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 119. Qiagen, Inc. Recent Developments
    Table 120. Rocheg Company Details
    Table 121. Rocheg Business Overview
    Table 122. Rocheg Pharmacogenomics (PGx) Product
    Table 123. Rocheg Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 124. Rocheg Recent Developments
    Table 125. Teva Pharmaceutical Industries Ltd. Company Details
    Table 126. Teva Pharmaceutical Industries Ltd. Business Overview
    Table 127. Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product
    Table 128. Teva Pharmaceutical Industries Ltd. Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 129. Teva Pharmaceutical Industries Ltd. Recent Developments
    Table 130. Thermo Fisher Scientific Company Details
    Table 131. Thermo Fisher Scientific Business Overview
    Table 132. Thermo Fisher Scientific Pharmacogenomics (PGx) Product
    Table 133. Thermo Fisher Scientific Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 134. Thermo Fisher Scientific Recent Developments
    Table 135. Transgenomic, Inc. Company Details
    Table 136. Transgenomic, Inc. Business Overview
    Table 137. Transgenomic, Inc. Pharmacogenomics (PGx) Product
    Table 138. Transgenomic, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024) & (US$ Million)
    Table 139. Transgenomic, Inc. Recent Developments
    Table 140. Research Programs/Design for This Report
    Table 141. Key Data Information from Secondary Sources
    Table 142. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Pharmacogenomics (PGx) Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Pharmacogenomics (PGx) Market Share by Type: 2023 VS 2030
    Figure 3. Polymerase Chain Reaction (PCR) Features
    Figure 4. Microarray Features
    Figure 5. Sequencing Features
    Figure 6. Other Features
    Figure 7. Global Pharmacogenomics (PGx) Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Pharmacogenomics (PGx) Market Share by Application: 2023 VS 2030
    Figure 9. Cardiovascular Diseases (CVD) Case Studies
    Figure 10. Central Nervous System (CNS) Case Studies
    Figure 11. Cancer/Oncology Case Studies
    Figure 12. Infectious Diseases Case Studies
    Figure 13. Other Case Studies
    Figure 14. Pharmacogenomics (PGx) Report Years Considered
    Figure 15. Global Pharmacogenomics (PGx) Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 16. Global Pharmacogenomics (PGx) Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 17. Global Pharmacogenomics (PGx) Market Share by Region: 2023 VS 2030
    Figure 18. Global Pharmacogenomics (PGx) Market Share by Players in 2023
    Figure 19. Global Top Pharmacogenomics (PGx) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics (PGx) as of 2023)
    Figure 20. The Top 10 and 5 Players Market Share by Pharmacogenomics (PGx) Revenue in 2023
    Figure 21. North America Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. North America Pharmacogenomics (PGx) Market Share by Type (2019-2030)
    Figure 23. North America Pharmacogenomics (PGx) Market Share by Application (2019-2030)
    Figure 24. North America Pharmacogenomics (PGx) Market Share by Country (2019-2030)
    Figure 25. United States Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Canada Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Europe Pharmacogenomics (PGx) Market Size YoY (2019-2030) & (US$ Million)
    Figure 28. Europe Pharmacogenomics (PGx) Market Share by Type (2019-2030)
    Figure 29. Europe Pharmacogenomics (PGx) Market Share by Application (2019-2030)
    Figure 30. Europe Pharmacogenomics (PGx) Market Share by Country (2019-2030)
    Figure 31. Germany Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. France Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. U.K. Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Italy Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Russia Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Nordic Countries Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. China Pharmacogenomics (PGx) Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. China Pharmacogenomics (PGx) Market Share by Type (2019-2030)
    Figure 39. China Pharmacogenomics (PGx) Market Share by Application (2019-2030)
    Figure 40. Asia Pharmacogenomics (PGx) Market Size YoY (2019-2030) & (US$ Million)
    Figure 41. Asia Pharmacogenomics (PGx) Market Share by Type (2019-2030)
    Figure 42. Asia Pharmacogenomics (PGx) Market Share by Application (2019-2030)
    Figure 43. Asia Pharmacogenomics (PGx) Market Share by Region (2019-2030)
    Figure 44. Japan Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. South Korea Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. China Taiwan Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. India Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Australia Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Size YoY (2019-2030) & (US$ Million)
    Figure 51. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Share by Type (2019-2030)
    Figure 52. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Share by Application (2019-2030)
    Figure 53. Middle East, Africa, and Latin America Pharmacogenomics (PGx) Market Share by Country (2019-2030)
    Figure 54. Brazil Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Mexico Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Turkey Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Saudi Arabia Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Israel Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. GCC Countries Pharmacogenomics (PGx) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 60. Abbott Laboratories Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 61. Affymetrix, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 62. Assurex Health, Inc Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 63. Astrazeneca Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 64. GeneDX Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 65. Illumina, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 66. Laboratory Corporation of America Holdings Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 67. Myriad Genetics, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 68. Pathway Genomics Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 69. Pfizer, Inc Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 70. Qiagen, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 71. Rocheg Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 72. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 73. Thermo Fisher Scientific Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 74. Transgenomic, Inc. Revenue Growth Rate in Pharmacogenomics (PGx) Business (2019-2024)
    Figure 75. Bottom-up and Top-down Approaches for This Report
    Figure 76. Data Triangulation
    Figure 77. Key Executives Interviewed